This RSA section is an unofficial mirror, is not legal advice, and may be incomplete, outdated, or incorrectly processed.

RSA 126-Z:8 · Statutory Construction

Title: X: PUBLIC HEALTH
Chapter: 126-Z · RIGHT TO TRY ACT
Status: current
Official source linked: Yes

Official source Copy section link

126-Z:8 Statutory Construction. – The general court enacts this chapter to promote maximum access by removing barriers in state law and indemnifying those involved in providing potentially life-saving treatments and treatments to improve the quality of patients' remaining life, to incentivize health care facilities, health care providers, manufacturers of drugs, biologics and/or devices, and other persons and entities involved in the care of patients, to treat terminal illness, whether through company-sponsored clinical trial, single-patient protocol, compassionate use protocol, or any other means of access to drugs, biologics, and/or devices which gathers information on patient outcomes, and to make New Hampshire a jurisdiction that attracts and fosters clinical trials and the development of drugs, biologics, and devices intended to treat terminal illness. This chapter shall be construed consistently with the general court's stated purpose. Source. 2025, 304:5, eff. Jan. 1, 2026.

Copy link

Source note

Source. 2025, 304:5, eff. Jan. 1, 2026.

Source history

2025, 304:5, eff. Jan. 1, 2026

Related materials

Bill relationships

2026 HB1292 amend · effective 2027-01-01
l and qualifying severe illness. This chapter shall be construed consistently with the general court's stated purpose. 5 New Section; Regenerative Stem Cell Therapies. Amend RSA 126-Z by inserting after section 8 the following new section: 126-Z:9 Regenerative Stem Cell Therapies. I. A physician may perform stem cell therapy that is not approved by the United States Food and Drug Administrati
2026 HB1292 amend · effective 2027-01-01
escreening with any patient, in any state or jurisdiction, who has been diagnosed by a physician with a terminal or qualifying severe illness. 4 Statutory Construction. Amend RSA 126-Z:8 to read as follows: 126-Z:8 Statutory Construction. The general court enacts this chapter to promote maximum access by removing barriers in state law and indemnifying those involved in providing potentially life-sav
2026 HB1292-FN amend · effective 2027-01-01
escreening with any patient, in any state or jurisdiction, who has been diagnosed by a physician with a terminal or qualifying severe illness. 4 Statutory Construction. Amend RSA 126-Z:8 to read as follows: 126-Z:8 Statutory Construction. The general court enacts this chapter to promote maximum access by removing barriers in state law and indemnifying those involved in providing potentially life-sav
2026 HB1292-FN amend · effective 2027-01-01
l and qualifying severe illness. This chapter shall be construed consistently with the general court's stated purpose. 5 New Section; Regenerative Stem Cell Therapies. Amend RSA 126-Z by inserting after section 8 the following new section: 126-Z:9 Regenerative Stem Cell Therapies. I. A physician may perform stem cell therapy that is not approved by the United States Food and Drug Administrati
2026 HB1735 amend
escreening with any patient, in any state or jurisdiction, who has been diagnosed by a physician with a terminal or qualifying severe illness. 3 Statutory Construction. Amend RSA 126-Z:8 to read as follows: 126-Z:8 Statutory Construction. The general court enacts this chapter to promote maximum access by removing barriers in state law and indemnifying those involved in providing potentially life-sa
2026 HB1735-FN amend
escreening with any patient, in any state or jurisdiction, who has been diagnosed by a physician with a terminal or qualifying severe illness. 3 Statutory Construction. Amend RSA 126-Z:8 to read as follows: 126-Z:8 Statutory Construction. The general court enacts this chapter to promote maximum access by removing barriers in state law and indemnifying those involved in providing potentially life-sa
2026 HB1809 reference · effective 2030-11-01
ryptamine, found in certain mushrooms, but does not include synthetic or synthetic analogs of psilocybin. VI. “Qualifying patient” means a patient whom a provider, as defined by RSA 126-ZZ:1, II, has diagnosed a medically appropriate candidate for the use of medical psilocybin based on being diagnosed with a qualifying condition. VII. “Qualifying condition” means any of the following: (a) Major treat
2026 HB1809-FN reference · effective 2030-11-01
ryptamine, found in certain mushrooms, but does not include synthetic or synthetic analogs of psilocybin. VI. “Qualifying patient” means a patient whom a provider, as defined by RSA 126-ZZ:1, II, has diagnosed a medically appropriate candidate for the use of medical psilocybin based on being diagnosed with a qualifying condition. VII. “Qualifying condition” means any of the following: (a) Major treat
2026 SB504 amend · effective 2027-01-01
screening with any patient, in any state or jurisdiction, who has been diagnosed by a physician with a terminal or qualifying severe illness. 19 Statutory Construction. Amend RSA 126-Z:8 to read as follows: 126-Z:8 Statutory Construction. The general court enacts this chapter to promote maximum access by removing barriers in state law and indemnifying those involved in providing potentially life-sa
2026 SB504 reference · effective 2027-01-01
nt, if applicable, that patient is liable for treatment expenses; and (6) A prominent statement that the patient is seeking treatment from an experimental treatment center under RSA 126-ZZ. II. “Experimental treatment” means the provision of a medical intervention by a health care provider involving an investigational drug, biologic, or device that has successfully completed phase one of a clinical t
2026 SB504-FN amend · effective 2027-01-01
screening with any patient, in any state or jurisdiction, who has been diagnosed by a physician with a terminal or qualifying severe illness. 19 Statutory Construction. Amend RSA 126-Z:8 to read as follows: 126-Z:8 Statutory Construction. The general court enacts this chapter to promote maximum access by removing barriers in state law and indemnifying those involved in providing potentially life-sa
2026 SB504-FN reference · effective 2027-01-01
nt, if applicable, that patient is liable for treatment expenses; and (6) A prominent statement that the patient is seeking treatment from an experimental treatment center under RSA 126-ZZ. II. “Experimental treatment” means the provision of a medical intervention by a health care provider involving an investigational drug, biologic, or device that has successfully completed phase one of a clinical t